Congenital Hypothyroid Screening among Low Birth Weight Infants
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Congenital Hypothyroid Screening among Low Birth Weight Infants

on

  • 451 views

 

Statistics

Views

Total Views
451
Views on SlideShare
451
Embed Views
0

Actions

Likes
1
Downloads
13
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Congenital Hypothyroid Screening among Low Birth Weight Infants Presentation Transcript

  • 1. Congenital Hypothyroid Screening among Low Birth Weight Infants, Michigan, 2005-2007 Steven J. Korzeniewski, MA, MSc, Maternal & Child Health Epidemiology Section Manager Violanda Grigorescu, MD, MSPH, William I. Young, Ph.D. Bureau of Epidemiology, Division of Genomics, Perinatal Health and Chronic Disease Epidemiology
  • 2. Outline
    • Brief overview of thyroid function and rationale for NICU protocol
    • NICU screening algorithm
    • Pre-Post NICU algorithm CH detection by birth weight
    • Concerns & discussion of newly detected cases (implications of three-year follow-up)
    • Conclusion/Public Health implications
  • 3. Hypothalamic-pituitary-thyroid axis
    • T 4 is stimulated by secretion of TSH by the pituitary.
    • Low T 4 (negative feedback) causes hypothalamus to secrete thyrotropin releasing hormone (TRH) which stimulates release of TSH thereby stimulating the thyroid gland to increase secretion of T 4 .
    • When the thyroid does not respond to TSH stimulation (primary CH), due to dysgenesis or dyshormonogenesis, the result is low T 4 and high TSH.
    Hypothalamus Pituitary Gland Thyroid (-) inhibition (+) stimulation TSH + T3, T4 - TRH + T3, T4 -
  • 4. CH Detection in Premature Infants
    • Maturity of the endocrine system influences initial dried blood spot TSH values.
      • Some premature infants with CH have late rising TSH and are therefore not detectable by an initial screen at 24-36hrs of life
    • NICU/LBW screening protocol implemented (2007) to account for unreliable screens in premature newborns
  • 5. NICU/LBW Screening Algorithm
  • 6. 1:1645 111893 68 1:1410 7050 5 1:211 2961 14 2007 1:1868 42961 23 1:1379 2757 2 1:199 996 5 1/1/08- 5/21/08 1:2283 114136 50 1:1460 7300 5 1:698 2793 4 2006 1:1863 108052 58 1:764 6873 9 1:517 2587 5 2005 Rate Screened Cases Rate Screened Cases Rate Screened Cases > 2500g 1800-2499g < 1800g Birth Weight Birth Year CH Cases by Birth Weight & Birth Year, Michigan, 1/1/2005-5/21/2008
  • 7. Number of Infants Screened by Birth Weight, Michigan, 2007   - 100 121,080 91.92 111,291 >=2500g 6,995 8.08 9,789 3.65 4,422 2200-2499g 2,573 4.43 5,367 1.28 1,554 2000-2199g 1,019 3.15 3,813 0.84 1,019 1800-1999g   - 2.31 2,794 2.31 2,794 < 1800g Estimated Number of Infants Added to the NICU Protocol (Cumulative) Cumulative % Cumulative Frequency % Frequency Birth Weight
  • 8. NICU Protocol Evaluation Conclusions
    • NICU protocol inclusion criteria currently does not consider gestational age.
      • GA is thought to be a better indicator of maturity than BW; however, concerns about data quality have led the latter to be used.
      • Adding very preterm and below (GA < 32 wks) infants would add 215 infants based on 2007 data.
    • We are evaluating the impact of:
      • increasing the birthweight inclusion criterion to ~2300g,
      • adding very preterm and below (GA < 32 wks) infants, and
      • eliminating 2 nd screens for infants born weighing less than ~1,000g-1,500g.
    • Clinical Laboratory Standards Institute (CLSI) has a subcommittee working on a proposed standard for NBS of SCBU/NICU infants
  • 9. Who are we detecting?
    • Is the 10 fold increase in risk of CH among infants < 1800g compared to those >= 1800g real ?
    • Standard of care is to follow-up CH cases until at least age three years (AAP Guidelines)
    • Diagnostic verification recommended (permanent vs. transient CH)
      • Thyroid function trial
    • Rate and outcome of diagnostic verification unknown
  • 10. CH Three Year Follow-up of ‘ Borderline ’ Cases
    • ‘ Borderline’ was initially considered as having pre-treatment serum TSH values below the 15 Th percentile.
      • We recently expanded our criteria to include cases below the 25th percentile and now plan to follow all cases to age 3 years.
    • Survey developed and pilot tested in collaboration with PEAC endocrinologists
    • Medical management data maintained by NBS Follow-up program used to locate cases’ physicians.
      • LTFU mitigated by use of MCIR and phone based survey
  • 11. Demographics of Michigan CH Cases Detected by NBS Classified by Pre-Treatment Serum TSH/FT4 Values, 9/2003-9/2007 25.8 58 53.1 3001 38.5 30.43% 70 FT4 >=.9, TSH <40 55.6 66.7 50 2461 34.1 3.91% 9 FT4 < .9, TSH < 40 18.2 33.3 61.5 3254 38 20.87% 48 FT4 >=.9, TSH >=40 19.6 39.2 79.1 3156 37.9 44.78% 103 FT4 < .9, TSH >=40 NICU (%) Male (%) White (%) Mean BW Mean GA % N Classification
  • 12.  
  • 13. Preliminary Findings of the CH Three year follow-up study
    • Preliminary findings indicate:
      • 47% (9/19) of cases with completed diagnostic re-evaluation to date appear not to have permanent CH.
      • A surprising number of patients (families) have stopped treatment of their own accord (7/23 with completed follow-up); this phenomenon requires further study.
        • One case (family) described miscommunication with health care provider and lack of follow-up as impetus to treatment cessation.
      • While all patients who stopped treatment on their own are thought to be transient CH (confirmation of transient CH is pending TSH value receipt- two patients have provided such confirmation to date), only 2/12 cases evaluated by an endocrinologist/hcp are considered transient.
        • This finding may have implications for the method of diagnostic re-evaluation.
        • Some cases were confirmed based on increasing treatment dosage at approximately 6 months of age; should this preclude three year thyroid challenge?
        • Questions remain about process and outcome of three year CH re-evaluation.
  • 14. Overall Conclusions
    • Newborn screening at 24-36hrs of life does not detect children with CH having late rising TSH
    • NICU screening protocols increase CH detection significantly
    • It is possible that some moderately LBW children having CH and late rising TSH remain undetected.
    • NICU algorithm inclusion criteria require further evaluation
      • Gestational age should likely be considered
    • It is possible that many borderline cases, which likely includes children with CH detected by the 2 nd or 3 rd screen, are transient
      • Such cases are more likely to be male, LBW, NICU births, and/or racial minorities
    • Three year follow-up is of critical importance to differentiate transient from permanent CH, particularly in states conducting routine second screens or having NICU/LBW protocols.
  • 15. Acknowledgements
    • Bill Young, Manger, Newborn Screening Follow-up Program
    • Violanda Grigorescu, Director, Division of Genomics, Perinatal Health & Chronic Disease Epidemiology
    • Newborn Screening Follow-up Staff
    • Pediatric Endocrine Advisory Committee
  • 16. Thank You [email_address] http://www.michigan.gov/mchepi